Calidi Biotherapeutics(CLDI) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results - Announced FDA Clearance of the Northwestern University IND Application for NeuroNova (CLD-101) Clinical Trial in High-Grade Glioma. - Presented data supporting RTNova (CLD-400), the company's systemic antitumor virotherapy platform, at the International Oncolytic Virotherapy Conference (IOVC) in Rotterdam, Netherlands, the Society for Immunotherapy of Cancer (SITC) Annual Meeting, and at Immuno US 2024 in San Di ...